Page 3 - Drug Manufacturers

Taliban sending Afghan women to prison for protection, says UN report

Taliban officials are sending Afghan women to prison to protect them from gender-based violence, according to a UN report published Thursday. Before the Taliban seized power in 2021, there were 23 state-sponsored women protection centers in Afghanistan where survivors of gender-based violence could seek refuge. Now there are none, the UN report said. Officials from the Taliban-led administration told the U.N. Assistance Mission in Afghanistan that there was no need for such shelters or that they were a Western concept. The Taliban sends women to prison if they have no male relatives to stay with or if the male relatives are considered unsafe, the report said. Authorities have also asked male relatives for commitments or sworn statements that they will not harm a female relative, inviting local elders to witness the guarantee, it added. Women are sent to prison for their protection akin to how prisons have been used to accommodate drug addicts and homeless people in Kabul, the repor

Johnson & Johnson sees 2024 sales growth slowing as top drug faces rivals

The pharma and medical devices giant will soon lose its exclusivity with psoriasis treatment Stelara, which accounted for a fifth of its drug sales in the third quarter

Pharma exports may return to double digit-growth rate: Pharmexcil

Bhaskar said while exports to North America were up 8.85 per cent during April-October, those to the US increased 9.58 per cent

Drug manufacturers in India benefit from Big Pharma interest beyond China

China has for nearly 20 years been the preferred location for a range of pharmaceutical research and manufacturing services due to the low cost and speed offered by contract drugmakers there

Strides Pharma gets USFDA approval for Levetiracetam Oral Solution

The Levetiracetam Oral Solution has a market size of around $55 million, according to data reported by IQVIA

Lupin introduces generic version of Zemuron Injection in United States

The newly introduced Rocuronium Bromide Injection is available in two formulations

Sanofi loses $21 bn in market value after dropping 2025 profit target

Sanofi shares trade at a 12 month forward price-to-earnings ratio of 11, a discount to AstraZeneca's 16 and global pharma index of 17, according to LSEG data

Drug regulatory reforms for improving quality

A strong drug regulation system is essential for India, as it not only supplies quality drugs to its own population but is responsible for meeting 20 per cent of the global demand

Zydus unit recalls 7,248 bottles of Oxybutynin Chloride tablets in US

A unit of Zydus Lifesciences is recalling over 7,000 bottles of Oxybutynin Chloride tablets in the US due to manufacturing issues, according to the US Food and Drug Administration (USFDA). As per its latest Enforcement Report, the US health regulator said the drugmaker is recalling 7,248 bottles of Oxybutynin Chloride extended-release tablets, used to treat overactive bladder and urinary conditions, in the US. New Jersey-based Zydus Pharmaceuticals (USA) Inc. is recalling the affected lot due to "Failed Dissolution Specifications", the USFDA stated. The lot was produced at Ahmedabad and distributed in the US by Zydus Pharmaceuticals (USA) Inc, the US health regulator stated. The drug firm initiated the Class II recall on September 21 this year. As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse hea

Drug regulator CDSCO finds syrups made by Norris Medicines toxic: Report

The drug regulator for Gujarat state, where Norris is based, told Reuters that its factory had been closed

WHO's good manufacturing norms to be made compulsory for all drug firms

Only 2,000 of the 10,500 manufacturing units in the country have the World Health Organization's GMP certification

WHO warns of a spurious rare disease drug Defitelio floating in India

The WHO said that the genuine manufacturer of Defitelio has confirmed that the product referenced in the alert is falsified

Jhunjhunwala family-backed Concord Biotech gains 27% on market debut

The strong listing follows healthy demand for the shares of Gujarat-based bulk drug maker in its Rs 1,551-crore initial public offering (IPO)

Health ministry proposes separate post for medical devices controller

Specific provision for recall of drugs and devices; penal provisions for substandard drugs

A critical lapse in Jan Vishwas Bill

In seeking to make life easier for entrepreneurs, the proposed new law raises several questions on patient safety

Centre moots unified portal for drug regulation to build trust in quality

Move seeks to harmonise regulatory requirements at central and state level

Indian drugs regulators took action against 105 pharma firms, says minister

Indian drugs regulators have taken action against 105 pharmaceutical companies after a risk-based inspection and audit of manufacturing plants, the health minister said on Tuesday

Boehringer Ingelheim names Gagandeep Singh as head of India pharma biz

Drug firm Boehringer Ingelheim on Monday said it has appointed Gagandeep Singh as head of the pharma business vertical for the Indian market. The company has appointed Singh as Managing Director and Head of Human Pharma India with effect from July 10. He will also join the Board of Boehringer Ingelheim India, the company said in a statement. Boehringer Ingelheim has three business areas -- Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. "Gagandeep's passion for fostering a customer-focused culture and his experience across complex health ecosystems will be invaluable to the organisation as we continue to strengthen our strategic and sustainability commitment to India," Boehringer Ingelheim Regional Managing Director and Head of Human Pharma for India, Middle East, Turkey and Africa Mohammed Tawil noted. Singh joins Boehringer Ingelheim from AstraZeneca, where he was the Managing Director for India and Africa Cluster Head. He succeeds Vani Manja, who mov

Big pharma: Here's why India's drug industry needs a major overhaul

The latest drug recalls just add to a long line of scandals that have tainted the pharma sector of India

Bitter medicine for pharma regulation

The Gambian tragedy has raised uncomfortable questions about drug regulation in India. The Truth Pill is a depressing but eye-opening reality check of the regulatory landscape